World Sickle Cell Day 2020

As the world grapples with the COVID-19 pandemic, we need to continue our efforts to support vulnerable populations, who may be more at risk, such as people with sickle cell disease (SCD).

Sickle cell disease is a hereditary and life-threatening condition that causes ongoing vascular damage and repeated injury to the blood vessels and organs, including the heart and lungs. This lifelong illness often takes an extreme emotional, physical, and financial toll on patients and their families.

A holistic …

/by

Novartis expands Africa Sickle Cell Disease program to Uganda and Tanzania

  • New collaborations aim to reduce the burden of sickle cell disease (SCD) in East Africa and improve access to high quality care
     
  • Program continues progress in Ghana with more than 2000 patients being treated with hydroxyurea in 11 treatment centers across the country
     
  • Novartis plans to roll the program out to a total of 10 African countries by 2022
     
  • Approximately 1 000 children in Africa are born with SCD every day and more than half will die before they reach the age of five1

    • …

/by

Novartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis

  • FDA approval for Cosentyx® is based on the Phase III PREVENT trial,  demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of the axial spondyloarthritis (axSpA) disease spectrum
     
  • There are an estimated 2.7M people living with axial spondyloarthritis (axSpA) in the US; however, it remains significantly underdiagnosed1,2
     
  • nr-axSpA approval is the fourth indication for Cosentyx, which is backed by five years of clinical data supporting …
/by

Day of the African Child 2020

UNICEF warns that an additional 6 000 children under five1 could die every day, without urgent action. On this Day of the African Child, Novartis remains committed to the health and wellbeing of Africa’s children.

An African child is 8 times more likely to die before his fifth birthday2 than one born in Europe. Pneumonia, diarrhea and malaria are the three biggest killer diseases of young children in Africa – representing 1 million deaths per year. In addition, sickle cell disease (SCD) is the single most important genetic cause of childhood mortality globally, …

/by

Standing for Racial Equity and Justice as One Novartis

We believe unequivocally that Black Lives Matter.

As a company focused on improving human health globally, we also recognize the disparities Black communities and communities of color face when it comes to health care. Our teams are working to ensure our company is providing resources to external organizations, including the NAACP Empowerment Program, to support their core work on health equity.

We are also working to increase patient diversity within our clinical research and development programs and continue our decades-long efforts to combat diseases that disproportionally …

/by

US FDA approves updated Novartis Beovu® label, to include additional safety information

  • Novartis worked with US Food and Drug Administration (FDA) to update Beovu (brolucizumab) prescribing information to guide healthcare professionals in their treatment of wet AMD patients1
     
  • The update includes characterization of adverse events, retinal vasculitis and retinal vascular occlusion, as part of the spectrum of intraocular inflammation observed in the HAWK & HARRIER trials and noted in the original prescribing information1
     
  • Novartis has convened a fully dedicated team collaborating with …
/by

Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma

  • Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a free combination of twice-daily Sal/Flu plus once-daily tiotropium (Tio), in improving quality of life in people with uncontrolled asthma1.
  • Among secondary analyses, improvements in lung function, asthma control, health status, and a reduction in moderate exacerbations were observed with once-daily high-dose IND/GLY/MF compared to a free combination of high-dose Sal/Flu plus Tio1. …
/by

Novartis PREVENT data show Cosentyx® helps patients realize early and lasting relief in axial spondyloarthritis

  • Phase III PREVENT data show Cosentyx® 150 mg provided significant and sustained improvement in signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) up to Week 521
     
  • nr-axSpA is the fourth EU indication for Cosentyx, providing patients in Europe with a first-in-class treatment that addresses the axial spondyloarthritis (axSpA) disease spectrum
     
  • There are approximately 1.7 million patients with nr-axSpA in the top five EU countries and US2
     
  • PREVENT is …
/by

Pride @ Novartis 2020 – inspired to make a difference

We each have a story to tell.  A community that contributes to who we are today.  Heroes who hold us up in the face of challenges.

Our stories are what make us exceptional – they inspire those around us but also future generations.  At Novartis, we want to build an inclusive environment that values each of our unique stories, because it’s our differences that enable our global impact.  Our shared stories offer new ways of seeing the world that can help us to reimagine medicine for people everywhere.

…

/by

Novartis provides update on FDA review of ofatumumab, a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis

Basel, June 2, 2020 —  Novartis today announced that it has received notice from the US Food and Drug Administration (FDA) that the agency has extended its review of the Supplemental Biologics License Application (sBLA) for ofatumumab (OMB 157), a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis. Regulatory action is now expected in September 2020.

“Novartis will continue to work with the FDA to complete the review as soon as possible,” said Marie-France Tschudin, President, Novartis Pharmaceuticals. “We are well prepared …

/by